NCT01481077View on ClinicalTrials.gov

A Dose Evaluation Study of the Effect of Plug Placement on the Efficacy and Safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma

PHASE2CompletedINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

November 30, 2011

Primary Completion Date

September 30, 2012

Study Completion Date

September 30, 2012

Conditions
GlaucomaOcular Hypertension (OH)
Interventions
DRUG

Latanoprost-PPDS

Sustained release for 12 weeks

Trial Locations (11)

19148

Philadelphia Eye Associates, Philadelphia

37803

University Eye Surgeons, Maryville

38119

Total Eye Care, P.A., Memphis

63090

Comprehensive Eye Care, Ltd, Washington

63131

Ophthalmology Consultants Inc., Des Peres

Ophthalmology Associates, St Louis

72762

Vold Vision, Springdale

80134

Glaucoma Consultants of Colorado, PC, Denver

89052

Las Vegas Physicians Research Group, Henderson

89148

Abrams Eye Institute, Las Vegas

06810

Danbury Eye Physicians & Surgeons, Danbury

Sponsors
All Listed Sponsors
lead

Mati Therapeutics Inc.

INDUSTRY

NCT01481077 - A Dose Evaluation Study of the Effect of Plug Placement on the Efficacy and Safety of the Latanoprost Punctal Plug Delivery System (L-PPDS) in Subjects With Ocular Hypertension or Open-Angle Glaucoma | Biotech Hunter | Biotech Hunter